Oppenheimer lowers Harmony Biosciences stock price target on model updates
Oppenheimer cut its Harmony Biosciences (NASDAQ:HRMY) price target to $70 from $85 but kept an Outperform rating after model updates. Harmony reported Q2 2026 Wakix net sales of $261.3M (+30% YoY) and reaffirmed full-year guidance of $1.00B to $1.04B. Oppenheimer cited new Phase 1 data for BP-205 and expects further Phase 1 readouts in Q4 2026 and early 2027.
How this was made
The 30-second read
Why it matters
The immediate tradable element is the analyst price-target reduction, while the fundamental trajectory hinges on upcoming BP-205 dose-escalation and volunteer studies and the Oct 22, 2026 Wakix IP resolution timeline.
Market read
A concrete sell-side PT cut tied to updated modeling assumptions, occurring alongside a Q2 beat and reaffirmed guidance, creates a mixed but tradable sentiment signal.
What to watch
Key upcoming catalysts are scheduled for Q4 2026 (multiple ascending dose) and early 2027 (sleep-deprived volunteer data), plus Wakix IP court proceedings on Oct 22, 2026.
Background
Oppenheimer updated its Harmony Biosciences model using actual results and adjustments, alongside newly cited Phase 1 BP-205 data.
Ticker impact
Oppenheimer cut Harmony Biosciences' price target to $70 from $85 while citing updated model inputs and Phase 1 BP-205 data.
Likely modest downside bias versus prior target, with follow-through dependent on Q4 2026 Phase 1 multiple-ascending-dose readout.
The article provides a concrete PT change and specific clinical/data milestones, but it is still an analyst model update rather than a new company disclosure.
Market effects
Reinforces that orexin-2/sleep-disorder biotech valuation is sensitive to early clinical dose-response assumptions and IP litigation timelines.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, as the catalyst is company-specific clinical and analyst modeling.
Counterpoint
Despite the PT cut, the company beat Q2 expectations, reaffirmed full-year revenue guidance, and reported no serious safety signals in early BP-205 Phase 1 data.
Key entities
- public_companyHarmony Biosciences Holdings Inc.
NASDAQ-listed biotech; Oppenheimer lowered its price target and cited BP-205 Phase 1 updates while the company reaffirmed 2026 guidance.
- drug_programBP-205
Orexin-2 agonist in Phase 1 for social anxiety disorder; early data cited as supporting once-daily dosing and selectivity.
- productWakix
Primary revenue driver; full-year 2026 guidance reaffirmed and IP court proceedings scheduled for Oct 22, 2026.
